USE OF OFF-LABEL MEDICATIONS IN A NEONATAL INTENSIVE CARE UNIT

USE OF OFF-LABEL MEDICATIONS IN A NEONATAL INTENSIVE CARE UNIT

This paper aims to analyze the use of off label (OL) medicines, according to the National Regulatory Agency, in a neonatal intensive care unit of a high-risk maternity hospital in Northeast Brazil. A cross-sectional study was carried out, using a convenience sample of newborns that used mechanical v...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Revista Paulista de Pediatria 2021-01, Vol.39, p.e2020063
Hauptverfasser: Koszma, Erica Inez Alves, Bispo, Ana Jovina Barreto, Santana, Isabelle Araujo de Oliveira, Santos, Catharine Natielle Oliveira Dias Belarmino Dos
Format: Artikel
Sprache:eng
Schlagworte:
Drug utilization
Infant, newborn
Intensive Care Units, Neonatal
Off-label use
Original
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page e2020063
container_title Revista Paulista de Pediatria
container_volume 39
creator Koszma, Erica Inez Alves
Bispo, Ana Jovina Barreto
Santana, Isabelle Araujo de Oliveira
Santos, Catharine Natielle Oliveira Dias Belarmino Dos
description This paper aims to analyze the use of off label (OL) medicines, according to the National Regulatory Agency, in a neonatal intensive care unit of a high-risk maternity hospital in Northeast Brazil. A cross-sectional study was carried out, using a convenience sample of newborns that used mechanical ventilation at the Intensive Care Unit. As a reference, OL medications were considered for those without an approval for newborn usage by the Brazilian Health Regulatory Agency (Agência Nacional de Vigilância Sanitária - ANVISA) and by the Food and Drugs Administration (FDA). The sample consisted of 158 newborns, 58.3% male, 87.7% premature, and 70.2% of low or very low birth weight. According to ANVISA, 440 out of the 1,167 prescriptions analyzed were OL, with 98.1% of newborns exposed to at least one of these drugs. According to the FDA, 484 prescriptions were OL, with 75.8% of newborns exposed to at least one of them. Anti-infectives were the most prescribed OL medications. Neonates who presented respiratory failure and pneumonia used these drugs more often; and there was no relation between their use and the number of deaths. Nearly all newborns at the Intensive Care Units, mainly preterm infants, are exposed to at least one off-label (OL) medication during hospital stay, according to the national and international regulatory agencies. No association was found between off-label prescriptions and the frequency of complications or neonatal deaths.
doi_str_mv 10.1590/1984-0462/2021/39/2020063
format Article
fullrecord <record><control><sourceid>pubmed_doaj_</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7802993</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_9006dede57dd4fe29ef01dcdcabad68c</doaj_id><sourcerecordid>33440406</sourcerecordid><originalsourceid>FETCH-LOGICAL-c528t-b0ff09e9a4cc891acae2b882fec3e20207e32545165eae387c26484010963393</originalsourceid><addsrcrecordid>eNpVke1KwzAUhoMobk5vQeoF1J18tE3-DOrstFA7cJ1_Q5aks2NbpZ2Cd2_q5nAQOCQn75MTHoTuMNzjQMAQC858YCEZEiB4SEVXAUJ6hvrH3jnqAwbqQ8BJD1217crdABxGl6hHKWPAIOyj0XyWeNOJWxM_ix-SzHtJHtNxXKTTfOaluRd7eTLN4yLO3K5I8ln6lnjj-DXx5nlaXKOLUq1be3OoA1RMkmL87GfTJ0fJfB0QvvMXUJYgrFBMay6w0sqSBeektJrabvbIUhKwAIeBVZbySJOQcebmFyGlgg5QuseaWq3kR1NtVPMta1XJ34O6WUrV7Cq9tlK4XxprbBAZw0pLhC0BG220WigTcu1Yoz3r43OxsUbb7a5R6xPoaWdbvctl_SUjDkQI6gBiD9BN3baNLY9ZDLLzIzsHsnMgOz-SCnnw47K3_x8_Jv-E0B8szYZU</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>USE OF OFF-LABEL MEDICATIONS IN A NEONATAL INTENSIVE CARE UNIT</title><source>Open Access: PubMed Central</source><source>Directory of Open Access Journals</source><source>EZB Electronic Journals Library</source><source>PubMed Central Open Access</source><creator>Koszma, Erica Inez Alves ; Bispo, Ana Jovina Barreto ; Santana, Isabelle Araujo de Oliveira ; Santos, Catharine Natielle Oliveira Dias Belarmino Dos</creator><creatorcontrib>Koszma, Erica Inez Alves ; Bispo, Ana Jovina Barreto ; Santana, Isabelle Araujo de Oliveira ; Santos, Catharine Natielle Oliveira Dias Belarmino Dos</creatorcontrib><description>This paper aims to analyze the use of off label (OL) medicines, according to the National Regulatory Agency, in a neonatal intensive care unit of a high-risk maternity hospital in Northeast Brazil. A cross-sectional study was carried out, using a convenience sample of newborns that used mechanical ventilation at the Intensive Care Unit. As a reference, OL medications were considered for those without an approval for newborn usage by the Brazilian Health Regulatory Agency (Agência Nacional de Vigilância Sanitária - ANVISA) and by the Food and Drugs Administration (FDA). The sample consisted of 158 newborns, 58.3% male, 87.7% premature, and 70.2% of low or very low birth weight. According to ANVISA, 440 out of the 1,167 prescriptions analyzed were OL, with 98.1% of newborns exposed to at least one of these drugs. According to the FDA, 484 prescriptions were OL, with 75.8% of newborns exposed to at least one of them. Anti-infectives were the most prescribed OL medications. Neonates who presented respiratory failure and pneumonia used these drugs more often; and there was no relation between their use and the number of deaths. Nearly all newborns at the Intensive Care Units, mainly preterm infants, are exposed to at least one off-label (OL) medication during hospital stay, according to the national and international regulatory agencies. No association was found between off-label prescriptions and the frequency of complications or neonatal deaths.</description><identifier>ISSN: 0103-0582</identifier><identifier>EISSN: 1984-0462</identifier><identifier>DOI: 10.1590/1984-0462/2021/39/2020063</identifier><identifier>PMID: 33440406</identifier><language>eng</language><publisher>Brazil: Sociedade de Pediatria de São Paulo</publisher><subject>Drug utilization ; Infant, newborn ; Intensive Care Units, Neonatal ; Off-label use ; Original</subject><ispartof>Revista Paulista de Pediatria, 2021-01, Vol.39, p.e2020063</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c528t-b0ff09e9a4cc891acae2b882fec3e20207e32545165eae387c26484010963393</citedby><cites>FETCH-LOGICAL-c528t-b0ff09e9a4cc891acae2b882fec3e20207e32545165eae387c26484010963393</cites><orcidid>0000-0002-7125-9349 ; 0000-0002-6228-768X ; 0000-0001-6464-9851 ; 0000-0001-8493-9864</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802993/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802993/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33440406$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Koszma, Erica Inez Alves</creatorcontrib><creatorcontrib>Bispo, Ana Jovina Barreto</creatorcontrib><creatorcontrib>Santana, Isabelle Araujo de Oliveira</creatorcontrib><creatorcontrib>Santos, Catharine Natielle Oliveira Dias Belarmino Dos</creatorcontrib><title>USE OF OFF-LABEL MEDICATIONS IN A NEONATAL INTENSIVE CARE UNIT</title><title>Revista Paulista de Pediatria</title><addtitle>Rev Paul Pediatr</addtitle><description>This paper aims to analyze the use of off label (OL) medicines, according to the National Regulatory Agency, in a neonatal intensive care unit of a high-risk maternity hospital in Northeast Brazil. A cross-sectional study was carried out, using a convenience sample of newborns that used mechanical ventilation at the Intensive Care Unit. As a reference, OL medications were considered for those without an approval for newborn usage by the Brazilian Health Regulatory Agency (Agência Nacional de Vigilância Sanitária - ANVISA) and by the Food and Drugs Administration (FDA). The sample consisted of 158 newborns, 58.3% male, 87.7% premature, and 70.2% of low or very low birth weight. According to ANVISA, 440 out of the 1,167 prescriptions analyzed were OL, with 98.1% of newborns exposed to at least one of these drugs. According to the FDA, 484 prescriptions were OL, with 75.8% of newborns exposed to at least one of them. Anti-infectives were the most prescribed OL medications. Neonates who presented respiratory failure and pneumonia used these drugs more often; and there was no relation between their use and the number of deaths. Nearly all newborns at the Intensive Care Units, mainly preterm infants, are exposed to at least one off-label (OL) medication during hospital stay, according to the national and international regulatory agencies. No association was found between off-label prescriptions and the frequency of complications or neonatal deaths.</description><subject>Drug utilization</subject><subject>Infant, newborn</subject><subject>Intensive Care Units, Neonatal</subject><subject>Off-label use</subject><subject>Original</subject><issn>0103-0582</issn><issn>1984-0462</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVke1KwzAUhoMobk5vQeoF1J18tE3-DOrstFA7cJ1_Q5aks2NbpZ2Cd2_q5nAQOCQn75MTHoTuMNzjQMAQC858YCEZEiB4SEVXAUJ6hvrH3jnqAwbqQ8BJD1217crdABxGl6hHKWPAIOyj0XyWeNOJWxM_ix-SzHtJHtNxXKTTfOaluRd7eTLN4yLO3K5I8ln6lnjj-DXx5nlaXKOLUq1be3OoA1RMkmL87GfTJ0fJfB0QvvMXUJYgrFBMay6w0sqSBeektJrabvbIUhKwAIeBVZbySJOQcebmFyGlgg5QuseaWq3kR1NtVPMta1XJ34O6WUrV7Cq9tlK4XxprbBAZw0pLhC0BG220WigTcu1Yoz3r43OxsUbb7a5R6xPoaWdbvctl_SUjDkQI6gBiD9BN3baNLY9ZDLLzIzsHsnMgOz-SCnnw47K3_x8_Jv-E0B8szYZU</recordid><startdate>20210101</startdate><enddate>20210101</enddate><creator>Koszma, Erica Inez Alves</creator><creator>Bispo, Ana Jovina Barreto</creator><creator>Santana, Isabelle Araujo de Oliveira</creator><creator>Santos, Catharine Natielle Oliveira Dias Belarmino Dos</creator><general>Sociedade de Pediatria de São Paulo</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-7125-9349</orcidid><orcidid>https://orcid.org/0000-0002-6228-768X</orcidid><orcidid>https://orcid.org/0000-0001-6464-9851</orcidid><orcidid>https://orcid.org/0000-0001-8493-9864</orcidid></search><sort><creationdate>20210101</creationdate><title>USE OF OFF-LABEL MEDICATIONS IN A NEONATAL INTENSIVE CARE UNIT</title><author>Koszma, Erica Inez Alves ; Bispo, Ana Jovina Barreto ; Santana, Isabelle Araujo de Oliveira ; Santos, Catharine Natielle Oliveira Dias Belarmino Dos</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c528t-b0ff09e9a4cc891acae2b882fec3e20207e32545165eae387c26484010963393</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Drug utilization</topic><topic>Infant, newborn</topic><topic>Intensive Care Units, Neonatal</topic><topic>Off-label use</topic><topic>Original</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Koszma, Erica Inez Alves</creatorcontrib><creatorcontrib>Bispo, Ana Jovina Barreto</creatorcontrib><creatorcontrib>Santana, Isabelle Araujo de Oliveira</creatorcontrib><creatorcontrib>Santos, Catharine Natielle Oliveira Dias Belarmino Dos</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Revista Paulista de Pediatria</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koszma, Erica Inez Alves</au><au>Bispo, Ana Jovina Barreto</au><au>Santana, Isabelle Araujo de Oliveira</au><au>Santos, Catharine Natielle Oliveira Dias Belarmino Dos</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>USE OF OFF-LABEL MEDICATIONS IN A NEONATAL INTENSIVE CARE UNIT</atitle><jtitle>Revista Paulista de Pediatria</jtitle><addtitle>Rev Paul Pediatr</addtitle><date>2021-01-01</date><risdate>2021</risdate><volume>39</volume><spage>e2020063</spage><pages>e2020063-</pages><issn>0103-0582</issn><eissn>1984-0462</eissn><abstract>This paper aims to analyze the use of off label (OL) medicines, according to the National Regulatory Agency, in a neonatal intensive care unit of a high-risk maternity hospital in Northeast Brazil. A cross-sectional study was carried out, using a convenience sample of newborns that used mechanical ventilation at the Intensive Care Unit. As a reference, OL medications were considered for those without an approval for newborn usage by the Brazilian Health Regulatory Agency (Agência Nacional de Vigilância Sanitária - ANVISA) and by the Food and Drugs Administration (FDA). The sample consisted of 158 newborns, 58.3% male, 87.7% premature, and 70.2% of low or very low birth weight. According to ANVISA, 440 out of the 1,167 prescriptions analyzed were OL, with 98.1% of newborns exposed to at least one of these drugs. According to the FDA, 484 prescriptions were OL, with 75.8% of newborns exposed to at least one of them. Anti-infectives were the most prescribed OL medications. Neonates who presented respiratory failure and pneumonia used these drugs more often; and there was no relation between their use and the number of deaths. Nearly all newborns at the Intensive Care Units, mainly preterm infants, are exposed to at least one off-label (OL) medication during hospital stay, according to the national and international regulatory agencies. No association was found between off-label prescriptions and the frequency of complications or neonatal deaths.</abstract><cop>Brazil</cop><pub>Sociedade de Pediatria de São Paulo</pub><pmid>33440406</pmid><doi>10.1590/1984-0462/2021/39/2020063</doi><orcidid>https://orcid.org/0000-0002-7125-9349</orcidid><orcidid>https://orcid.org/0000-0002-6228-768X</orcidid><orcidid>https://orcid.org/0000-0001-6464-9851</orcidid><orcidid>https://orcid.org/0000-0001-8493-9864</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0103-0582
ispartof Revista Paulista de Pediatria, 2021-01, Vol.39, p.e2020063
issn 0103-0582
1984-0462
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7802993
source Open Access: PubMed Central; Directory of Open Access Journals; EZB Electronic Journals Library; PubMed Central Open Access
subjects Drug utilization
Infant, newborn
Intensive Care Units, Neonatal
Off-label use
Original
title USE OF OFF-LABEL MEDICATIONS IN A NEONATAL INTENSIVE CARE UNIT
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T07%3A50%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=USE%20OF%20OFF-LABEL%20MEDICATIONS%20IN%20A%20NEONATAL%20INTENSIVE%20CARE%20UNIT&rft.jtitle=Revista%20Paulista%20de%20Pediatria&rft.au=Koszma,%20Erica%20Inez%20Alves&rft.date=2021-01-01&rft.volume=39&rft.spage=e2020063&rft.pages=e2020063-&rft.issn=0103-0582&rft.eissn=1984-0462&rft_id=info:doi/10.1590/1984-0462/2021/39/2020063&rft_dat=%3Cpubmed_doaj_%3E33440406%3C/pubmed_doaj_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/33440406&rft_doaj_id=oai_doaj_org_article_9006dede57dd4fe29ef01dcdcabad68c&rfr_iscdi=true